Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-14), Proteomics International Laboratories's Beta is -0.5457.
Proteomics International Laboratories (ASX:PIQ) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
Proteomics International Laboratories Beta Related Terms
Proteomics International Laboratories Beta Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Proteomics International Laboratories's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteomics International Laboratories Beta vs Biotechnology Industry
Proteomics International Laboratories Beta Calculation
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Proteomics International Laboratories (ASX:PIQ) has a Beta of -0.5457 as of Jul. 14, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Proteomics International Laboratories and its competitors.
Is Proteomics International Laboratories' Beta too high?
Proteomics International Laboratories' current Beta is -0.5457. Overall, Proteomics International Laboratories has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Proteomics International Laboratories' Beta compare to VRTX and REGN?
Proteomics International Laboratories' Beta of -0.5457 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Proteomics International Laboratories and its competitors. Proteomics International Laboratories's current Beta is -0.5457. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteomics International Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Proteomics International Laboratories (ASX:PIQ) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.48, compared to a current price of A$0.20 — trading 59.4% below its estimated fair value. The current Beta is -0.5457. Proteomics International Laboratories' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Proteomics International Laboratories (ASX:PIQ), the current Beta is -0.5457 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Proteomics International Laboratories (ASX:PIQ) Overvalued in 2026?
Based on GuruFocus' analysis, Proteomics International Laboratories stock appears to be undervalued.
The current stock price of A$0.20 is trading 59.4% below its estimated GF Value™ of A$0.48.
GuruFocus considers Proteomics International Laboratories to be Possible Value Trap.
Key valuation signals for ASX:PIQ:
Beta: -0.5457
GF Value™: A$0.48 vs. price of A$0.20 (59.4% below fair value)
No single metric tells the full story. See the ASX:PIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Proteomics International Laboratories Business Description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
31GF Score
Get the complete analysis for ASX:PIQ
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PIQ has been successfully added to your 
